Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
3,182,163
-
Total 13F shares
-
37,683,440
-
Share change
-
-2,194,897
-
Total reported value
-
$47,102,000
-
Price per share
-
$1.25
-
Number of holders
-
60
-
Value change
-
-$3,931,122
-
Number of buys
-
22
-
Number of sells
-
43
Institutional Holders of Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) as of Q3 2022
As of 30 Sep 2022,
Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) was held by
60 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,683,440 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Versant Venture Management, LLC, Frazier Life Sciences Management, L.P., Lynx1 Capital Management LP, New Leaf Venture Partners, L.L.C., VANGUARD GROUP INC, Deep Track Capital, LP, BlackRock Inc., RENAISSANCE TECHNOLOGIES LLC, and HIGHLINE CAPITAL MANAGEMENT, L.P..
This page lists
62
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.